Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia
Posted inCardiology Critical Care news

Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia

This 2-year follow-up of the TTM2 trial demonstrates that targeted hypothermia at 33°C provides no long-term benefit for functional or cognitive recovery compared to targeted normothermia. The findings emphasize the importance of early fever management and suggest a recovery plateau after six months post-arrest.
Subglottic Suction and Polyurethane Cuffs Fail to Improve Outcomes in Emergency Intubation: Insights from the PreVent 2 Trial
Posted inCritical Care Emergency Medicine news

Subglottic Suction and Polyurethane Cuffs Fail to Improve Outcomes in Emergency Intubation: Insights from the PreVent 2 Trial

The PreVent 2 trial demonstrates that specialized endotracheal tubes with subglottic suction and polyurethane cuffs do not significantly reduce ventilator-associated complications or improve 6-month laryngeal, cognitive, or quality-of-life outcomes compared to standard PVC tubes in emergency settings.
Cerebral Oximetry-Guided Treatment Significantly Stabilizes Oxygenation in Extremely Preterm Infants: Results from a Randomized Clinical Trial
Posted inCritical Care news Pediatrics

Cerebral Oximetry-Guided Treatment Significantly Stabilizes Oxygenation in Extremely Preterm Infants: Results from a Randomized Clinical Trial

A randomized trial involving 100 extremely preterm infants shows that cerebral oximetry-guided treatment using a standardized guideline and NIRS device significantly reduces the burden of cerebral hypoxia and hyperoxia during the first five days of life, potentially improving neuroprotective care.
Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality
Posted inCritical Care Infectious Diseases news

Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality

The Phase IIa INSPIRE trial demonstrates that early administration of anakinra, guided by the presepsin biomarker, reduces the risk of organ dysfunction by 30% and significantly improves 90-day survival in hospitalized pneumonia patients, marking a major step forward for precision medicine in critical care.
Mechanical Thrombectomy Superior to Anticoagulation Alone for Rapid Right Ventricular Recovery in Intermediate-High Risk Pulmonary Embolism: Results from the STORM-PE Trial
Posted inCardiology Critical Care news

Mechanical Thrombectomy Superior to Anticoagulation Alone for Rapid Right Ventricular Recovery in Intermediate-High Risk Pulmonary Embolism: Results from the STORM-PE Trial

The STORM-PE trial, the first randomized controlled trial of its kind, demonstrates that computer-assisted vacuum thrombectomy (CAVT) significantly improves right ventricular recovery and reduces clot burden compared to anticoagulation alone in patients with intermediate-high risk pulmonary embolism.
Decompressive Craniectomy Benefits Persist Across Deep Intracerebral Hemorrhage Locations: A SWITCH Trial Analysis
Posted inCritical Care Neurology news

Decompressive Craniectomy Benefits Persist Across Deep Intracerebral Hemorrhage Locations: A SWITCH Trial Analysis

A post hoc analysis of the SWITCH trial demonstrates that the clinical benefits of decompressive craniectomy in reducing death and severe disability are consistent across different anatomical locations of deep supratentorial intracerebral hemorrhage, including the basal ganglia, internal capsule, and thalamus.